CTOs on the Move

University of Vermont - College of Medicine

www.vtahec.org

 
University of Vermont - College of Medicine is a Burlington, VT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.vtahec.org
  • 1 S Prospect St
    Burlington, VT USA 05401
  • Phone: 802.656.2179

Executives

Name Title Contact Details

Similar Companies

TigerConnect

TigerConnect is healthcare`s most widely adopted communication platform – uniquely modernizing care collaboration among doctors, nurses, patients, and care teams. TigerConnect is the only solution that combines a consumer-like user experience for text, video, and voice communication with the serious security, privacy, and clinical workflow requirements that today`s healthcare organizations demand. TigerConnect accelerates productivity, reduces costs, and improves patient outcomes. Trusted by more than 5,000 healthcare organizations, TigerConnect maintains 99.99% verifiable uptime and processes more than 10 million messages each day.

NeoPath Health

NeoPath Health is a Hopkins, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Hughes BioPharma Advisers

Hughes BioPharma Advisers is a Darien, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Focus Diagnostics

Focus Diagnostics is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Focus Diagnostics is based in Cypress, CA. You can find more information on Focus Diagnostics at www.focusdx.com

Questcor

We are a biopharmaceutical company focused on the treatment of patients with serious, difficult-to-treat autoimmune and inflammatory disorders. Our efforts are currently focused on the fields of neurology, nephrology and rheumatology, areas of medicine which have significant unmet medical needs. Our main product is H.P Acthar® Gel (repository corticotropin injection), a naturally-derived formulation of adrenocorticotropic hormones used in a variety of disorders having an inflammatory component. We are currently supporting research in a number of rare conditions, where there is significant unmet need for treatment alternatives to standard therapies. We are also actively supporting research efforts to better understand disease processes and therapeutic mechanisms of action in conditions where Acthar might potentially play a role in treatment.